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Abstract 
The objective of this study was to identify the impact of professional knowledge and 
education on a willingness to participate in clinical trials. It hypothesized that there is no 
statistical difference in the median rank score between clinical research professionals and 
other post-graduate educated participants. The research question asked whether the 
clinical research program graduates were more inclined to participate in clinical trials than 
other groups with a post-graduate education. A cross-sectional quantitative study of 83 
clinical research professionals was conducted. All participants were invited to complete a 
shortened version of the Center for Information and Study on Clinical Research 
Participation (CISCRP) survey assessing their willingness to participate in clinical trials. 
This study showed that there is a significant difference between the two groups. Although 
some factors must be considered when determining their actual participation rate, these 
findings should not discourage recruiting clinical research professionals into clinical trials.  
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I. Introduction 
A large proportion of research on potential participants within the clinical research 
professionals remains incomplete. Patient recruitment targeted typical and more 
traditional populations. However, clinical research professionals and the post-graduate 
public with clinical knowledge are a considerable population to be studied. Knowledge of 
the clinical research professionals’ willingness to participate in clinical trials might 
enhance the diversity and effectiveness of recruitment. The objectives of this study were 
to identify the impact of professional knowledge in clinical research in the willingness to 
participate in clinical trials compared to other educated populations. This study aimed to 
better understand the barrier of recruiting different human subjects into clinical research.  
There is a lack of knowledge of clinical research professionals’ willingness to 
participate in clinical trials. Observing the differences in willingness to participate in 
clinical trials between the post-graduate public and clinical research professionals is 
required. The assumption is that there is no statistical difference in the median rank score 
between clinical research professionals and the other post-graduate participants. 
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II. Review of Literature 
Clinical trials are the application of exploring the updates of therapies and 
preventions in medical science. Although the objective of the clinical trial is to deliver a 
maximum expectation of care and to enrich science, a limited number of patients are 
enrolled in clinical trials (Sood et al., 2009). One of the factors of success of clinical trials 
is enrolling the target population of the intended treatment or prevention. According to 
Sood et al. (2009), the assessment of patients’ perspectives of clinical studies indicates 
that 68% responded positively to the idea of participating in clinical trials. However, 82% 
were unaware of how to access information about clinical trials for their disease. 
Therefore, recruitment of patients should be more efficient to update medical care and 
disease prevention through the application of clinical trials.  
Recruitment of patients for clinical trials has been getting attention in the clinical 
research field recently. The processes of recruiting and retaining patients are becoming 
more complicated, which delays drug development (Findlay, 2009). According to English, 
Lebovitz and Giffin (2010), this delay is costing the clinical research industry money, 
time, and resources, depending on the type of trial, populations, and research setting. The 
overall estimate of the cost of delay is up to $300–$600 million to implement, conduct, 
and monitor a large, multicenter trial to completion (Institute of Medicine [US]) Forum on 
Drug Discovery, 2010). Speeding patients’ recruitment is attainable to enhance the overall 
clinical trial enterprise by recognizing the factors of participation.  
Willingness to participate in clinical trials is one of the factors of participation. 
According to Gul and Ali (2010), most studies have focused on the willingness of patients 
and their families to participate in clinical trials. However, a recent survey from the 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
3 
Center for Information and Study on Clinical Research Participation (CISCRP; 2015) 
found that approximately 80% of the general population had a positive predilection to be 
involved in clinical trials. These participants comprise a large part of the participants in 
potential therapies and protection trials. Therefore, the public perspective and willingness 
to participate are significant in the clinical trial enterprise. 
Patients have various reasons for participating in clinical trials. According to 
Brintnall-Karabelas et al. (2011) and Getz (2014), even if the participants are qualified to 
enroll in the clinical trials, they have concerns about receiving placebo, adverse effects, 
medical exposure, confidentiality, and unexpected costs. Interestingly, the CISCRP (2015) 
revealed that 43% of the public perceived the side effects as a major risk of participating 
in clinical trials, while only 28% related their contribution to helping medical science and 
potential therapies. This result is similar to the Teschke et al. (2010) study, which showed 
that possible medical advantages to the person or community encourage participation in 
clinical trials. Respondents were highly concerned either their diseases or their relatives’ 
condition. Approximately 25% were unwilling to participate, while 29% were unsure 
about contributing to clinical trials (Teschke et al., 2010). The public seems to consider 
the benefits and risks before they join any clinical trials.  
Willing and unwilling groups have different characteristics. According to Teschke 
et al. (2010), the characteristics of willing participants included having a sick family 
member, being elderly, prior involvement in clinical research, or having a positive 
inclination toward clinical trial participation. Research results were also a great motivator. 
However, the characteristics of unwilling respondents included post-graduate education 
and an attitude, depending on the objective of the trial, toward clinical trial participation 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
4 
(Teschke et al., 2010). According to Nelson, Martin and Getz (2015), 18 - 34-year-olds 
were the least willing to participate in clinical trials compared with older generations. In 
addition, the younger generation had diverse concerns of health issues, such as weight 
control, healthy lifestyle, and prevention of diseases, which were different than the 
perception of the older generations (Nelson et al., 2015). The characteristics of willing 
and unwilling participants vary based on their clinical trial perspectives, which determine 
their willingness to participate.  
In addition, willingness to participate in clinical trials differs from the public to 
specific patient groups. As explained earlier, the public might consider their participation 
as social contribution while patients might consider their health status before participation 
in clinical trials. According to English, Lebovitz and Giffin (2010), patients have different 
perceptions depending on their disease type and severity. Around 68% of patients were 
willing to participate in clinical trials, while 82% were unfamiliar with the clinical trials 
on their illness (Sood et al., 2009). Agoritsas, Deom and Perneger (2011) found that 
patients appreciated the contribution of clinical trials if these trials were safe and suitable 
and if they had adequate information from their physicians. Consequently, patients were 
willing to participate in clinical trials if they had sufficient knowledge about the trials.  
Research has shown that patients’ education about the research could enhance 
their participation in clinical trials, but there is limited research on the level of education 
as a factor associated with a willingness to participate in clinical trials. According to 
Fayed (2016), the clinical trial type and complexity affect decisions to participate in 
clinical trials. About 80% of healthcare providers surveyed were willing to participate in 
clinical trials. However, they were more willing to participate in surveys than trials with 
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intervention or new therapies for diseases. Also, a recent study by Bouida et al. (2016) 
stated that 89% of physicians were willing to participate in clinical trials. The main 
encouragement was enhancing science, while the largest reason for reluctance was the 
complications. Despite the willingness of professionals to participate in clinical trials, the 
level of education is a factor that distinguishes the public from professionals. 
Similarly, the public, healthcare providers, or professionals were equally 
concerned about the complications of the clinical trials. According to Fayed (2016), 
87.2% of healthcare providers were concerned about adverse events, and 79.5% had 
issues about the endpoints of clinical trials. Despite their background, they were hesitant 
about the significance behind these clinical trials. Although there is a lot of research on 
public perception, professional willingness to participate in clinical trials needs more 
attention.  
According to the literature, there is a lack of knowledge about clinical research 
professionals’ willingness to participate in clinical trials. Earlier literature concentrated on 
patients, patients’ families, patients at risk, and the general public’s willingness to 
participate in clinical trials. However, only a limited number of studies reported how 
willing professionals are to participate in clinical trials. Therefore, there is a need to 
investigate the willingness of clinical research professionals to participate in clinical trials. 
Studying clinicians or professionals and their willingness to participate in clinical 
trials will help researchers recognize if there is potential for new volunteers with new 
perceptions and experiences, or if a potential specialty could affect the willingness to 
participate in clinical trials. The assumption is that clinical research professionals would 
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be as willing to participate in clinical trials as the public. This study aims to observe the 
differences, if they occur, in willingness to participate in clinical trials between 
individuals with a post-graduate education and clinical research professionals. The post-
graduate population from the CISCRP (2015) was compared to alumni of the Clinical 
Research Administration Graduate Program of Eastern Michigan University.  
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III. Research Design and Methodology 
Research Question 
Are clinical research administration program graduates more inclined to 
participate in clinical trials than other groups with a post-graduate education? 
Research Objective 
The objectives of this study were to identify the impact of professional knowledge 
and education on a willingness to participate in clinical trials.  
Research Hypothesis 
There is no statistical difference in the median rank score between clinical 
research professionals and other post-graduate educated participants. 
Research Subjects  
Respondents with a post-graduate education in the Center for Information and 
Study on Clinical Research Participation (CISCRP) study were compared to clinical 
research professionals who were 2000 to 2015 alumni of the clinical research 
administration graduate program at Eastern Michigan University. Differences in 
willingness to participate in clinical trials were evaluated. Current students who have not 
yet graduated from the CRA program were excluded. The CRA respondents were 97.59% 
USA residents; therefore, they were compared to the US post-graduate participants of the 
CISCRP survey.  
Research Methods 
CISCRP database. The CISCRP, an independent nonprofit organization, 
conducted an online international survey in 2015, titled ‘‘The 2015 CISCRP Perceptions 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
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& Insights Study: Report on General Perceptions.’’ The study presents valued and 
substantive insights into actionable ways that stakeholders of the clinical trials can better 
comprehend and more adequately engage with the general population and study 
participants. The overall results and subgroup differences are presented by demographic 
data, education level, income, age, and severity of the disease. 
The total number of survey respondents to the CISCRP survey was more than 
12,000 people. The US residents and post-graduates (e.g. master’s or doctorate level 
degrees) of the CISCRP numbered 560 participants. The aggregated data of the subgroup 
was obtained from CISCRP and compared to the data of the CRA study focusing on one 
question of importance: How willing are you to participate in a clinical research study? 
There were five survey responses options: I am not sure, not at all willing, not very 
willing, somewhat willing, very willing, and I am not sure. 
CRA data. A cross-sectional quantitative study of a purposive sample of 419 
clinical research professionals derived from the clinical research administration 
department database was approved by the University Human Subjects Review Committee 
(UHSRC) of Eastern Michigan University. See Appendix A. The number of respondents 
totaled 83 participants or approximately 20% of the purposive sample. Of the respondents, 
67.47% were employed in clinical research. All participants were invited to complete a 
shortened version of the CISCRP published survey after giving consent to participate in 
the study. The informed consent document is in Appendix B. The survey was open for 
two weeks. See Appendix C for the survey. 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
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The first part of the electronic survey queried demographic data such as residency, 
age, race, gender, employment status, occupation, and income. The second part of the 
survey assessed willingness to participate in clinical trials. It involved a question about 
willingness to participate in clinical trials as a research subject. There were five survey 
responses options: I am not sure, not at all willing, not very willing, somewhat willing, 
very willing, and I am not sure. In addition, a question was posed regarding their efforts to 
join a clinical trial, and actual participation. This question was a direct yes or no question. 
Other detailed questions examined the reasons that most people participate in clinical 
trials, how these people perceive clinical research, and what kind of information they need 
to participate as a research subject. Participants were required to evaluate their level of 
agreement to some statements. In addition, one question determined the perception of the 
level of safety of clinical trials by asking participants to state one of the following 
answers: very safe, somewhat safe, not very safe, or not at all safe. Finally, participants 
were asked to specify possible benefits and risks of participating in clinical trials.  
Data Management 
Data were collected from Survey Monkey and exported to a secured Microsoft 
Excel file. The secured file was double locked, including passwords for the laptop and 
Microsoft Excel file. The survey instrument itself did not collect any personal 
identification information. Statistical analyses were conducted using IBM SPSS Statistics 
24, and the data were exclusively aggregated. Several different statistical tests were also 
conducted on the data of this study: a set of Spearman’s correlations, several chi-square 
analyses, and odds ratio calculation. 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
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The Spearman's rank-order correlation (often abbreviated to Spearman's 
correlation) calculates a coefficient, rs or ρ, which is a measure of the strength and 
direction of the association between two continuous or ordinal variables. It is also, a 
measure of the significance of the relationship between two measures, which can be 
ordinal, interval, or ratio. Spearman’s rho can vary from -1 to +1, with -1 indicating a 
perfect negative correlation, zero indicating no correlation, and +1 indicating a perfect 
positive correlation. This test was chosen to determine whether there is an association 
between safety, age, willingness to patriciate in clinical trials, and other ordinal variables 
among CRA participants.  
Several one-sample chi-square analyses were conducted on these data. This test is 
used in order to determine whether there is a significant difference between responses 
given to some question; these responses are categorical, and some expected distribution. 
This test compares the actual responses provided by individuals with the expected 
distribution, which is specified by the researcher, in order to determine whether these two 
distributions are significantly different. 
In addition, an odds ratio was calculated in the dataset question of CRA graduates 
or post-graduates CISCRP. It is a measure of association between an exposure and an 
outcome; the ratio of the probability that an event will occur to the probability that it will 
not occur, and it can be any number between zero and infinity. The odds ratio was 
calculated focusing upon the measure of willingness or unwillingness and its relationship 
with the dataset in the willingness question. Within the context of the current study, this 
odds ratio showed how much more likely respondents are to be willing to participate in 
clinical trials among those in the post-graduates CISCRP as compared with those in the 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
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CRA graduates group. This odds ratio provided information about the association between 
these two measures over and above that obtained from a simple cross tabulation or chi-
square test. 
Participants’ Consent 
Participants were introduced to the study survey through an invitation E-mail 
(Appendix D and E) which included the following: study title, study objectives, study 
procedure, voluntary rights, expected risks, expected benefits, dissemination of results, 
confidentiality, and contact information. See Appendix B for informed consent. 
Therefore, participants who were willing to participate followed the hyperlink to the 
survey in the E-mail. The introductory page of the survey covered the consent information 
of participating in the intended study and the voluntary rights to completing the survey.  
Confidentiality 
The survey was anonymous. The researcher and statistician involved in this study 
had access to the responses. Otherwise, information provided was compiled with other 
scores and turned into statistical data. 
Ethical Aspects 
The University Human Subjects Review Committee (UHSRC) of Eastern 
Michigan University reviewed and approved this study before the research was 
conducted. See Appendix A.  
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IV. Results 
Spearman’s Correlation 
Four hundred and eleven CRA graduates were invited to participate in the current 
study, among which 83 participants accepted to join the study; the response rate was 20%. 
The objective of the study was to identify the impact of professional knowledge and 
education on willingness to participate in clinical trials. Theresore, a series of Spearman 
rank order correlation were performed on the ordinal variables to assess the association 
between the perception of the safety of the clinical research and the willingness to 
participate in clinical trials among graduates of Eastern Michigan University clinical 
research administration program, and the other study variables. A summary of the results 
can be found in Table 1. 
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Table 1 Spearman’s Correlations 
Spearman’s Correlations 
 
In the correlations conducted with the safety of clinical trials, three significant 
correlations were found in total. The correlation between the participant's perception of 
the safety of the clinical research and willingness to participate was a strong positive 
(Cohen, 1988): rs(76) = .503, (p = .001). A weak positive correlation (rs = .279,   
p = 0.013, df = 76) was found between the participant's perception of the safety of the 
clinical research and their age. The correlation between the participant's perception of the 
safety of the clinical research and how much time is spent at doctor's office was a weak 
positive (rs = .008, p = 0.947, df = 77). A weak positive correlation (rs = .137, p = 0.233, 
df = 76) was found between the participant's perception of the safety of the clinical 
research and receiving more time and attention from medical experts. The correlation was 
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a weak positive (rs = .105, p = 0.362, df = 76) between the participant's perception of the 
safety of the clinical research and potential risks and benefits of the study. A weak 
negative correlation (rs = -.087, p = 0.448, df = 76) was found between the participant's 
perception of the safety of the clinical research and the length of research participation. 
Similarly, a weak negative correlation (rs = -.054, p = 0.638, df = 76) was found between 
the participant's perception of the safety of the clinical research and the types of medical 
procedures of the research. The correlation was a weak positive (rs = .032, p = 0.748,      
df = 76) between the participant's perception of the safety of the clinical research and 
potential risks and the purpose of the clinical research study. A weak positive correlation 
(rs = .094, p = 0.416, df = 75) was found between the participant's perception of the safety 
of the clinical research and no risks are involved in the research. The correlation was a 
weak positive (rs = .074, p = 0.524, df = 75) between the participant's perception of the 
safety of the clinical research and doctor’s recommendation. A weak positive correlation 
(rs = .198, p = 0.085, df = 75) was found between the participant's perception of the safety 
of the clinical research and free treatment. The correlation was moderate positive   
(rs = .335, p = 0.003, df = 75) between the participant's perception of the safety of the 
clinical research and the convenience of the participation. 
In the correlations conducted with the willing to participate in clinical trials, four 
significant correlations were found. The correlation was a weak positive (rs = .289,  
p = 0.011, df = 74) between the participants’ willingness to participate in clinical trials and 
'their age. The correlation between the participants’ willingness to participate in clinical 
trials and how much time is spent at doctor's office was a weak positive (rs = .272,           
p = 0.016, df = 76). A weak positive correlation (rs = .146, p = 0.206, df = 75) was 
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found between the participants’ willingness to participate in clinical trials and receiving 
more time and attention from medical experts. The correlation was a weak positive  
(rs = .109 p = 0.343, df = 76) between the participants’ willingness to participate in 
clinical trials and potential risks and benefits. A weak negative correlation (rs = -.185,  
p = 0.105, df = 76) was found between the participants’ willingness to participate in 
clinical trials and the length of research participation. Similarly, a weak negative 
correlation (rs = -.051, p = 0.657, df = 76) was found between the participants’ 
willingness to participate in clinical trials and the types of medical procedures of the 
research. The correlation was a weak positive (rs = .101 p = 0.378, df = 76) between the 
participants’ willingness to participate in clinical trials and the purpose of the clinical 
research study. A weak positive correlation (rs = .138, p = 0.232, df = 75) was 
found between the participants’ willingness to participate in clinical trials and no risks are 
involved in the research. The correlation was a weak positive (rs = .200 p = 0.080,           
df = 75) between the participants’ willingness to participate in clinical trials and doctor’s 
recommendation. A moderate positive correlation (rs = .303, p = 0.007, df = 75) was 
found between the participants’ willingness to participate in clinical trials and free 
treatment. The correlation was a weak positive (rs = .245 p = 0.032, df = 75) between the 
participants’ willingness to participate in clinical trials and the convenience of the 
participation. 
In the correlations conducted with particpants’ age, one significant correlation was 
found in total. A weak positive correlation (rs = .106, p = 0.357, df = 75) was found 
between the participant's age and how much time is spent at doctor's office. The 
correlation was a weak positive (rs = .084 p = 0.472, df = 74) between the participant's 
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age and receiving more time and attention from medical experts. A weak positive 
correlation (rs = .076, p = 0.512, df = 74) was found between the participant's age and 
potential risks and benefits. A weak negative correlation (rs = -.040, p = 0.729, df = 74) 
was found between the participant's age and the length of research participation. The 
correlation was weak positive (rs = .0954 p = 0.412, df = 74) between the participant's age 
and the types of medical procedures of the research. The correlation between the 
participant's age and the purpose of the clinical research study was a weak positive          
(rs = .101 p = 0.378, df = 76). A weak positive correlation (rs = .176, p = 0.132, df = 73) 
was found between the participant's age and no risks are involved in the research. The 
correlation was a weak positive (rs = .013 p = 0.912, df = 73) between the participant's 
age and doctor’s recommendation. A weak positive correlation (rs = .074, p = 0.526,       
df = 73) was found between the participant's age and free treatment. The correlation 
between the participant's age and the convenience of the participation was a weak positive 
(rs = .031 p = 0.793, df = 73).  
In the correlations conducted with the time spent in doctor's office, one significant 
correlation was found in total. A moderate positive correlation (rs = .330, p = 0.003,        
df = 76) was found between how much time is spent at the doctor's office and receiving 
more time and attention from medical experts. The correlation between how much time is 
spent at doctor's office and potential risks and benefits was a weak positive (rs = .004,      
p = 0.971, df = 76). The correlation was a weak positive (rs = .043 p = 0.710, df = 76) 
between how much time is spent at doctor's office and the length of research participation. 
A weak positive correlation (rs = .062, p = 0.592, df = 76) was found between how much 
time is spent at doctor's office and the types of medical procedures of the research. A 
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weak negative correlation (rs = -.105, p = 0.358, df = 76) was found between how much 
time is spent at doctor's office and the purpose of the clinical research study. The 
correlation was a weak positive (rs = .201 p = 0.079, df = 75) between how much time is 
spent at doctor's office and no risks are involved in the research. A weak negative 
correlation (rs = -.048, p = 0.678, df = 75) was found between how much time is spent at 
doctor's office and doctor’s recommendation. Similarly, a weak negative correlation       
(rs = -.006, p = 0.961, df = 75) was found between how much time is spent at doctor's 
office and free treatment. The correlation between how much time is spent at doctor's 
office and the convenience of the participation was a weak positive (rs = .090 p = 0.435, 
df = 75). 
In the correlations conducted with receiving more time and attention from medical 
experts, two significant correlations were found in total. The correlation was a weak 
positive (rs = .158 p = 0.170, df = 75) between receiving more time and attention from 
medical experts and potential risks and benefits. A weak positive correlation (rs = .154,    
p = 0.182, df = 75) was found between receiving more time and attention from medical 
experts and the length of research participation. Similarly, a weak positive correlation    
(rs = .219, p = 0.056, df = 75) was found between receiving more time and attention from 
medical experts and the types of medical procedures of the research. The correlation was a 
weak positive (rs = .013 p = 0.914, df = 75) between receiving more time and attention 
from medical experts and the purpose of the clinical research study. A weak positive 
correlation (rs = .193, p = 0.096, df = 74) was found between receiving more time and 
attention from medical experts and no risks are involved. The correlation between 
receiving more time and attention from medical experts and doctor’s recommendation 
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was a weak positive (rs = .013 p = 0.914, df = 75). A weak positive correlation (rs = .283 
p = 0.013, df = 74) was found between receiving more time and attention from medical 
experts and free treatment. The correlation was a moderate positive (rs = .344 p = 0.002, 
df = 74) between receiving more time and attention from medical experts and the 
convenience of the participation.  
In the correlations conducted with potential risks and benefits, seven significant 
correlations were found in total. A weak positive correlation (rs = .288, p = 0.011,           
df = 76) was found between potential risks and benefits and the length of research 
participation. The correlation was a moderate positive (rs = .408 p = 0.001, df = 76) 
between potential risks and benefits and the types of medical procedures of the research. 
A strong positive correlation (rs = .617, p = 0.001, df = 76) was found between potential 
risks and benefits and the purpose of the clinical research study. The correlation was a 
moderate positive (rs = .374 p = 0.001, df = 75) between potential risks and benefits and 
no risks are involved in the research. A weak positive correlation (rs = .267, p = 0.019,    
df = 75) was found between potential risks and benefits and doctor’s recommendation. 
Similarly, a weak positive correlation (rs = .245, p = 0.032, df = 75) was found between 
potential risks and benefits and free treatment. The correlation was a weak positive        
(rs = .255 p = 0.025, df = 75) between potential risks and benefits and the convenience of 
the participation.  
In the correlations conducted with length of research participation, three 
significant correlations were found in total. A strong positive correlation (rs = .649,          
p = 0.001, df = 76) was found between the length of research participation and the types of 
medical procedures of the research. The correlation was a moderate positive (rs = .333,    
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p = 0.003, df = 76) between the length of research participation and the purpose of the 
clinical research study. A weak positive correlation (rs = .094, p = 0.416, df = 75) was 
found between the length of research participation and no risks are involved in the 
research. The correlation was a weak positive (rs = .257,  p = 0.024, df = 75) between the 
length of research participation and doctor’s recommendation. Similarly, the correlation 
was a weak positive (rs = .096,  p = 0.406, df = 75) between the length of research 
participation and free treatment. A weak positive correlation (rs = .172,  p = 0.135,          
df = 75) was found between the length of research participation and the convenience of 
the participation.  
In the correlations conducted with types of medical procedures of the research, 
two significant correlations were found in total. A moderate positive correlation             
(rs = .324, p = 0.004, df = 76) was found between the types of medical procedures of the 
research and the purpose of the clinical research study. The correlation was a weak 
positive (rs = .196, p = 0.088, df = 75) between the types of medical procedures of the 
research and no risks are involved in the research. Similarly, the correlation was a weak 
positive (rs = .138,      p = 0.231, df = 75) between the types of medical procedures of the 
research and doctor’s recommendation. A weak positive correlation (rs = .195, p = 0.008, 
df = 75) was found between the types of medical procedures of the research and free 
treatment. The correlation between the types of medical procedures of the research and 
the convenience of the participation was a weak positive (rs = .229, p = 0.045, df = 75). 
In the correlations conducted with the purpose of the clinical research study, four 
significant correlations were found in total. A moderate positive correlation (rs = .334,     
p = 0.003, df = 75) was found between the purpose of the clinical research study and no 
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risks are involved in the research. Similarly, a moderate positive correlation (rs = .314,     
p = 0.005, df = 75) was found between the purpose of the clinical research study and 
doctor’s recommendation. Also, the correlation between the purpose of the clinical 
research study and free treatment was a moderate positive correlation (rs = .320,               
p = 0.005, df = 75). The correlation was a weak positive (rs = .264, p = 0.020, df = 75) 
between the purpose of the clinical research study and the convenience of the 
participation.  
In the correlations conducted with no risks are involved in the research, three 
significant correlations were found in total. A weak positive correlation (rs = .298,           
p = 0.008, df = 75) was found between no risk are involved in the research and doctor’s 
recommendation. The correlation was a weak positive (rs = .290, p = 0.011, df = 75) 
between no risks are involved in the research and free treatment. However, a moderate 
positive correlation (rs = .469, p = 0.001, df = 75) was found between no risks are 
involved in the research and the convenience of the participation.  
The correlation was a moderate positive (rs = .431, p = 0.001, df = 75) between 
doctor’s recommendation and free treatment. In addition, a moderate positive correlation 
(rs = .300, p = 0.008, df = 75) was found between doctor’s recommendation and the 
convenience of the participation. However, the correlation was a moderate positive  
(rs = .461, p = 0.001, df = 75) between free treatment and the convenience of the 
participation.  
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Chi-Square Goodness-of-Fit 
The hypothesis of this study proposed that there is no statistical difference in the 
median rank score between CRA professionals and other post-graduate educated 
participants, and therefore an exact chi-square goodness-of-fit test was performed on the 
graduate sample of CRA to determine if this sample was representative of the post-
graduates nationwide sample conducted by the CISCRP. There were significant 
differences in the distribution of responses to participants’ willingness to participate in 
clinical research X2(2) = 97.723,   (p < .001). See Table 2 for a comparison of the clinical 
research administration (CRA) Program graduate sample and the post-graduate of the 
CISCRP sample data.  
Table 2 A Comparison of Two Groups Regarding the Willingness to Participate in Clinical Trials 
 
A Comparison of the Two Groups Regarding the Willingness to Participate  
in Clinical Trials 
 
CRA Graduates’ 
Willingness 
CISCRP Post-graduates’ 
Willingness 
 N % N % 
I am not sure  6 7.6 6 1 
Not at all willing  5 6.4 3 0.5 
Not very willing 4 5.1 11 1,9 
Somewhat willing 40 51.2 229 40.8 
Very willing 23 29.4 311 55.5 
 
Of the 78 CRA graduates that participated in this survey, six individuals were not 
sure to participate, five individuals were not at all willing, four were not very willing, 40 
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individuals were somewhat willing, and 23 individuals were very willing. In contrast, of 
560 post-graduates of the CISCRP sample, six individuals were not sure to participate, 
three individuals were not at all willing, 11 were not very willing, 229 individuals were 
somewhat willing, and 311 individuals were very willing. Accordingly, the CISCRP post-
graduates were more willing than CRA graduates while CRA graduates are somewhat 
more willing to participate in clinical trials. 
In order to identify the impact of professional knowledge and education on a 
willingness to participate in clinical trials, several variables or facto rs should be 
considered. First, a comparison was conducted between the CRA graduates sample and 
the CISCRP sample with regard to their perception of clinical trials safety. See Table 3. 
There were significant differences in the distribution of responses to participants’ 
perception of clinical trials safety. Over 95% of the responses of both groups were 
characterized clinical trials as safe. Therefore, the perception of the safety of clinical trials 
in CRA graduates and CISCRP post-graduates are the same.  
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Table 3 Perception of Safety in Clinical Trials Among CRA and CISCRP 
Perception of Safety in Clinical Trials Among CRA and CISCRP  
 CRA graduates’ 
perception of safety of 
clinical trials 
CISCRP post-graduates’ 
perception of safety of 
clinical trials 
 Count % Count % 
Not safe 4 5.0% 7 1.25% 
Safe 76 95% 553 98.75% 
Total 80 100.0% 560 100.0% 
 
Second, a comparison was conducted between CRA graduates and the post-
graduates CISCRP sample on regard to the greater risk associated with the clinical trials. 
See Table 4. Almost similar percentage of considering the possibility of side effects as the 
greatest risk associated with clinical trial participation; CISCRP responses were 59% 
while CRA graduates were 56%. However, the lowest percentages were not the same 
among both groups; the lowest percentage was 1.3% in CRA sample, which no risks are 
involved, and the lowest risk was 1% in CISCRP sample who thought that there was a 
possibility of stopping treatments that proved some benefits.  
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Table 4 The Greater Risk Associated with Clinical Trials Among CRA and CISCRP 
The Greater Risk Associated with Clinical Trials Among CRA and CISCRP 
 CRA graduates’ 
perception of 
the greater risk 
CISCRP post-
graduates’ perception 
of the greater risk 
 N % N % 
Possibility of side effects 45 56.3% 330 59% 
Possibility of receiving a placebo or 
inactive drug  
8 10.0% 109 19% 
Possible risks to my overall health 16 20.0% 91 16% 
Possibility of stopping treatments that 
may be providing some benefit to me 
already 
4 5.0% 7 1% 
I do not believe there are risks 1 1.3% 18 3% 
 
Another chi-square test was performed between the two groups. One-sample chi-
square test was conducted on a willingness to participate, with a significant result being 
found, χ2(4) = 97.723, p < .001. The two groups were statistically different, which is not 
appropriate to compare between aggregated results of the CISCRP and individual 
responses of CRA results. This indicated a significant difference between the observed 
and expected frequencies, which are summarized in Table 5. These results indicate a 
substantially greater likelihood of the CRA responding with I am not sure, Not at all 
willing, Not very willing, and Somewhat willing as compared with the expected 
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frequencies with a substantially lower likelihood of the CISCRP responding with Very 
willing as compared with what was expected if the groups were equal. Therefore, if the 
CRA followed the same distribution of the CISCRP, they should have the expected 
frequencies of the CISCRP. 
Table 5 One-Sample Chi-Square Analysis: Willingness to Participate in A Clinical Trial 
One-Sample Chi-Square Analysis: Willingness to Participate in A Clinical Trial 
Response Category CRA 
“Observed” N 
CISCRP 
“Expected” N 
Residual 
I am not sure 6 .8 5.2 
Not at all willing 5 .4 4.6 
Not very willing 4 1.5 2.5 
Somewhat willing 40 31.9 8.1 
Very willing 23 43.3 -20.3 
Total 78   
 
An additional chi-square test was conducted on a willingness to participate of the 
sample of CRA to determine if this sample was previously participated in clinical trials. 
As presented in Table 6, out of 78 participants, one graduate participated though he was 
unsure of his willingness, and seven participants, who were somewhat willing, 
participated in clinical trials. However, ten graduates were very willing to participate in 
clinical trials, and13 participants already enrolled in clinical trials. Accordingly, 57 
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participants had not participated previously in clinical trials regardless of their 
willingness.  
Table 6 Chi-Square Analysis: Willingness to Participate and Previous Participation 
Chi-Square Analysis: Willingness to Participate and Previous Participation 
 
Previously Participated in  
Clinical Research Trials Total 
 No  % Yes  % 
Willingness 
to 
participate 
in Clinical 
Research 
Study 
I am not sure 5 83.3% 1 16.7% 6 100% 
Not at all willing 5 100% 0 0.0% 5 100% 
Not very willing 4 100% 0 0.0% 4 100% 
Somewhat 
willing 
33 82.5% 7 17.5% 40 100% 
Very willing 10 43.5% 13 56.5% 23 100% 
 Total 57 73.1% 21 26.9% 78 100% 
 
Odds Ratio  
Table 7 presents the results of the cross tabulation conducted between CRA 
graduates and post-graduate CISCRP measures. Seventy-two participants in the study of 
CRA graduates responded to willingness question. However, the majority were willing to 
participate in clinical trials (n = 63). A similar trend was found of the 554 participants of 
the post-graduates CISCRP study. Among those with post-graduate CISCRP participants, 
the majority were willing to participate (n = 540). The odds ratio of post-graduate 
CISCRP respondents indicating willingness to participate in clinical research versus 
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respondents from CRA graduates is 5.510 CI [2.292, 13.246], which was calculated as 
(540/14)/(63/9). See Table 8. Post-graduate CISCRP were 5.51 times more likely to state 
that they were willing to participate in clinical research than CRA graduates.  
Table 7 Cross Tabulation Between Willing or Unwilling and Dataset 
Cross Tabulation Between Willing or Unwilling and Dataset 
 Dataset  
Groups CRA Graduates 
Post-Graduates 
CISCRP  
Total 
Willing 63 540 603 
Unwilling 9 14 23 
Total 72 554 626 
 
Table 8 Risk Estimate 
Risk Estimate 
  95% Confidence Interval 
 Value Lower Upper 
Odds Ratio for Willing or Unwilling 5.510 2.292 13.246 
CRA graduates Dataset 3.745 2.138 6.562 
CISCRP Post-Graduates Dataset .680 .489 .944 
N of Valid Cases 626   
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Themes 
CRA graduate results showed a strong theme regarding a medical or scientific 
contribution. Out of 80 responses to the greatest benefit of participating in clinical trials, 
49 responses were advancing the science, which was around 61.25%. See Figure 1. In 
addition, about 65.82% strongly agreed on the scientific contribution as a perception of 
how some people feel about clinical trials. See Figure 2. 
 
Figure 1. Greatest Benefit of Participating in Clinical Trials. 
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Figure 2. CRA Professionals’ Perception on How Some People are Contributing to 
Science by Clinical Trials. 
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V. Discussion  
Discussion 
The exact chi-square goodness-of-fit rejected the null hypothesis of this study. The 
willing to participate in clinical trials was compared between the clinical research 
administration (CRA) study sample and the post-graduate Center for Information and 
Study on Clinical Research Participation (CISCRP) sample. The CRA graduates, who 
were 67.47% of the study’s participants employed in clinical research, were somewhat 
more willing to participate in clinical trials than the sample of the post-graduate CISCRP. 
Although there was a significant difference between the two groups, it is difficult to state 
which group was more willing due to the residual value were missing between the CRA 
observed frequencies and the CISCRP expected frequencies. However, if we grouped the 
responses of those who were willing and somewhat willing, 80.7% of the CRA graduates 
were willing to participate in clinical trials, while the post-graduate CISCRP respondents 
were 93% more willing. Therefore, there is a difference between the two groups.  
In addition, the odds ratio test demonstrated that CRA graduates were 7 times 
more likely to say that they were willing to participate in clinical trials, while CISCRP 
post-graduates were 38.57 times more likely to say that they were willing to participate in 
clinical trials. Accordingly, CISCRP post-graduates were 5.51 times more likely to state 
that they were willing to participate in clinical trials than CRA graduates. The odds ratio 
which is 5.51, supported the difference between the two groups as CRA graduates were 
less willing to participate in clinical trials. 
However, the study sample of CRA graduates showed that the potential 
willingness to participate in clinical trials is highly associated with certain factors. These 
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factors consisted of the following: age, time allocated to the doctor’s office, free treatment 
and convenience of research participation, unavailability of other medical options, the 
treatment’s assisting other patients, and the reasonability of the time commitment. 
Interestingly, the influence of the time commitment and the convenience of the clinical 
research could be due to demand jobs; 67.47% of the study’s participants were employed 
in clinical research, which positively reflected on their behavior in and interpretations of 
clinical trials. In addition, the effect of personal advantages on participation in clinical 
trials was acceptable, as the study’s sample was more willing to participate if the 
treatment was free of charge. Moreover, there was a positive correlation between trusting 
physicians’ recommendations and the potential willingness to participate in clinical trials 
if there were scientific or social benefits without minimal side effects associated with the 
treatment, as well as sharing of a summary of research trial results with participants. 
Accordingly, there were as potential willingness to participate in clinical trials in CRA 
graduates regardless of their actual participation. 
The results of the CRA graduates study acknowledged that the willingness to 
participate in clinical trials affected the behavior of participants. About 17.5% of those 
who were somewhat willing to participate and 56.5% who were very willing previously 
participated in clinical trials. Thus, participants who were involved in clinical trials were 
more willing to enroll in clinical studies. However, 73.1% of the total participants had not 
participated previously in clinical trials regardless of their willingness. This result 
indicated that their specialty and education affected their behavior of participation by 
being more skeptical and more aware of the effect of some variables such as time 
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commitment, side effects and adverse events. Therefore, potential participants with less 
serious health conditions tend to be highly skeptical of participating.  
Being skeptical has not always had a negative impact. The CRA graduates' 
skepticism could be justified according to the importance of research objectives. In 
addition, sometimes there is a need to be skeptical of science especially in clinical 
research field due to the frequencies of errors or a large amount of expected and 
unexpected adverse events in clinical trials. Thus, having scientific doubts implies 
prioritizing evidence. 
To support the skeptical of clinical research, a comparison of the CRA graduates 
and CISCRP post-graduates indicated that the professional knowledge and education had 
not impacted the overall perception of the safety profile of clinical trials. Both groups 
were aware of the careful conduction of clinical trials as they are the fastest and safest 
way to find treatments that work in people and to improve health. In addition, CRA 
graduates and post-graduates CISCRP had the same level of risk involvement in clinical 
trials. Both groups considered the possibility of side effects the greater risk. Due to their 
education level, they were knowledgeable of the medical consequences and unpleasant 
side effects that might occur during the participation in a clinical trial. Although both 
groups had post-graduate degrees, one of the CRA graduates and 18 of the CISCRP post-
graduates selected no risks are involved in clinical trials. Yet, the safety of clinical trials 
and risks involvement in clinical trials are acknowledged.  
In addition, CRA graduates’ results showed a strong theme, which is participation 
in clinical trials was considered a medical or scientific contribution. First, according to 
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CRA responses, the greatest benefit of participating in clinical trials is advancing the 
science. Second, CRA graduates’ perceptions of how some people feel about clinical trials 
strongly agreed that clinical trials considered a scientific contribution. This result 
interpreted the reseaon of that CRA graduates were less willing to participate in clincal 
trials as they were interested in the field as scientists more than clinical research 
participants.  
Research Limitations 
All participants were invited to complete a shortened version of the CISCRP 
published survey. Consequently, the language and items of the survey were not 
customized to the appropriate knowledge of CRA graduates to ensure the exposure to the 
same survey content of the two groups.  
The research question could be answered, and the results could be accurately 
interpreted if we could extract the individual responses from the CISCRP survey. Due to 
the need of subgroup analysis of nationwide post-graduate in the CISCRP survey, it was 
difficult to apply a new research question to their data. Therefore, the aggregated 
responses were interpreted in a comparison of this research data. 
This study has surveyed the alumni of the clinical research administration graduate 
program at Eastern Michigan University, these respondents might not reflect all clinical 
research professionals due to the low responses rate. Thus, the results could decrease the 
possibility of the generalizability of the findings. In addition, the comprehension of the 
nature of the clinical trials of this sample of the population may affect their perception of 
participation in clinical trials positively or negatively.  
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Suggestions for Further Research 
More quantitative research on potential participants of those who are post-graduate 
or have a clinical specialty, such as clinical research professionals, should be conducted. 
Researchers should identify the barriers and motivations of professionals’ participation. In 
addition, quantitative research should be conducted to test the time commitment of 
clinical research professionals as a factor that influences their participation due to the high 
percentage of the CRA sample who had not previously participate in clinical trials. 
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VI. Conclusion 
Overall, this study found that there is a significant difference between the clinical 
research administration program graduates and the post-graduate Center for Information 
and Study on Clinical Research Participation (CISCRP) in terms of their willingness to 
participate in clinical trials. The CRA professionals were less willing to participate in 
clinical trials than the post-graduate CISCRP. Although some factors must be considered 
when attempting actual participation, knowledge and professional background affected 
the willingness to participate in clinical trials. These results are justifiable, as the studied 
sample is more knowledgeable about clinical research and have more concerns about their 
participation. This conclusion must not affect the decision of recruiting clinical research 
professionals in clinical trials. Rather, this work is intended to indicate some of the 
differences between the two groups.  
  
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
36 
References 
Agoritsas, T., Deom, M., & Perneger, T. V. (2011). Study design attributes influenced 
patients’ willingness to participate in clinical research: A randomized vignette-
based study. Journal of Clinical Epidemiology, 64(1), 107–115. 
Bouida, W., Grissa, M. H., Zorgati, A., Beltaief, K., Boubaker, H., Sriha, A., Boukef, R., 
& Nouira, S. (2016). Willingness to participate in health research: tunisian survey. 
BMC Medical Ethics, 17, 47. 
Brintnall-Karabelas, J., Sung, S., Cadman, M. E., Squires, C., Whorton, K., & Pao, M. 
(2011). Improving recruitment in clinical trials: Why eligible participants decline. 
Journal of Empirical Research on Human Research Ethics, 6(1), 69–74. 
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd Edition.). 
Hillsdale, N.J.: Lawrence Erlbaum. 
English, R., Lebovitz, Y., & Giffin, R. (2010). Transforming clinical research in the 
United States: Challenges and opportunities: Workshop summary. Washington, 
D.C.: National Academies Press. Retrieved October 28, 2016, from 
http://www.nap.edu/catalog/12900 
Fayed, A. (2016). Willingness of a sample of health professionals to participate in clinical 
research as research subjects. International Journal of New Technology and 
Research (IJNTR), 2(1), 17–21. 
Findlay, S. (2009). Outsourcing clinical trials: Growth continues. Pharmaceutical 
Technology Europe, 21(5), 51–52. 
Getz, K. A. (2014). New insights into study volunteer perceptions and experiences to 
inform patient-centric clinical trials. Clinical Researcher, 28(2), 17–21. 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
37 
Gul, R. B., & Ali, P. A. (2010). Clinical trials: The challenge of recruitment and retention 
of participants. Journal of Clinical Nursing, 19(1–2), 227–233. 
Institute of Medicine (US) Forum on Drug Discovery, D. (2010). Challenges in clinical 
research. National Academies Press (US). Retrieved February 20, 2017, from 
https://www.ncbi.nlm.nih.gov/books/NBK50888/ 
Nelson, A. M., Martin, I. G., & Getz, K. A. (2015). Generational value differences 
affecting public perceptions of and willingness to participate in clinical trials. 
Therapeutic Innovation & Regulatory Science, 49(6), 940–946. 
Sood, A., Prasad, K., Chhatwani, L., Shinozaki, E., Cha, S. S., Loehrer, L. L., & Wahner-
Roedler, D. L. (2009). Patients’ attitudes and preferences about participation and 
recruitment strategies in clinical trials. Mayo Clinic Proceedings, 84(3), 243–247. 
Teschke, K., Marino, S., Chu, R., Tsui, J. K. C., Harris, M. A., & Marion, S. A. (2010). 
Public opinions about participating in health research. Canadian Journal of Public 
Health/Revue Canadienne de Sante’e Publique, 101(2), 159–164. 
 
  
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
38 
Appendix 
  
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
39 
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Appendix B: Informed Consent for Participation in Clinical Research 
 
Dear Participant, 
You are invited to participate in this research as one of the alumni of the Clinical 
Research Administration Graduate Program at Eastern Michigan University. 
Research Objective: To identify your willingness to participate in clinical trials. 
Voluntary Participation: You are completely free to choose whether to join the 
study or not. You have the right of withdrawal from the study at any time. However, we 
would appreciate your full participation. 
Study Procedures: If you decide to participate in this study, you will fill out the 
survey about your willingness to participate in clinical trials. It should take about 7-12 
minutes of your time. 
Expected Risks: There are no anticipated risks to participation. 
Expected Benefits: You will not directly benefit from participating in this study. 
Revision and Approval: The University Human Subjects Review Committee 
(UHSRC) of Eastern Michigan University revised and approved this study. 
Dissemination of Results: Results of this study may be presented publicly and/or 
published in a scientific journal. A copy of the study results will be sent to all alumni via 
E-mail. 
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Confidentiality: This is an anonymous survey. The researcher and statistician 
involved in this study will only have access to your responses. Otherwise, the information 
you provide will be compiled with other data and reported statistically.  
Contact Information: This study is graduate research for a Masters’ degree. If you 
have any questions or concerns, you can contact the researcher, Rania Felemban, at 
rfelemba@emich.edu. You can also contact the advisor, Dr. Irwin Martin, at 
imartin2@emich.edu. 
Statement of Consent: As a respondent, I understand my rights as a participant in 
the above-described study and voluntarily consent to participate and follow the 
requirements. Additionally, I understand the purpose, intent, and necessity of the study I 
will be participating in, and I understand that if I do not, I may ask questions. 
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Appendix C: Survey Form 
1) Where do you currently reside?  
☐ USA 
☐ India  
☐ Canada  
☐ Europe 
☐ Other (please specify) ………………. 
2) Which race/ethnicity best describes you? (Please choose one only) 
☐ Asian 
☐ African 
☐ Hispanic/Latino 
☐ White/Caucasian 
☐ Other (please specify) ………………. 
3) What is your gender? 
☐ Male 
☐ Female 
4) What is your age? (type age in box below) 
…………………………. 
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5) How would you describe your employment status? 
☐ Employed full-time 
☐ Employed part-time 
☐ Unemployed/looking for work 
☐ Student 
☐ Homemaker 
☐ Retired 
☐ Other (please specify) ………………. 
6) Are you employed in clinical research now? 
☐ Yes 
☐ No 
7) If no, what is your position? 
………………. 
8) What was your total household income before taxes during the past 12 months in 
US dollars? 
☐ Less than $25,000 USD 
☐ $25,000 USD to $34,999 USD 
☐ $35,000 USD to $49,999 USD 
☐ $50,000 USD to $74,999 USD 
☐ $75,000 USD to $99,999 USD 
CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS 
44 
☐ $100,000 USD to $124,999 USD 
☐ $125,000 USD to $149,999 USD 
☐ $150,000 USD or more 
☐ Decline to respond 
9) In your opinion, how safe are clinical research studies? 
☐ Very safe 
☐ Somewhat safe 
☐ Not very safe 
☐ Not at all safe 
10) Which one of the following do you consider to be the greatest risk of 
participating in a clinical research study? (select one) 
☐ Possibility of side effects 
☐ Possibility of receiving a placebo or inactive drug (sugar pill) 
☐ Possibility of making my private medical information public 
☐ Possible risks to my overall health 
☐ Possibility of stopping treatments that may be providing some benefit to me already 
☐ None - I do not believe there are risks 
☐ Other (please specify) ………………. 
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11) Which one of the following do you consider to be the greatest benefit of 
participating in a clinical research study? (select one) 
☐ May help advance science and the treatment of my disease/condition 
☐ May help save or improve the lives of other patients with my disease/condition 
☐ May help improve my disease/condition 
☐ May provide monetary compensation (money) for participation 
☐ May guide understanding of how available medications compare with a new treatment 
☐ May provide free medication (if applicable in your country) 
☐ May provide free medical procedures and care (if applicable in your country) 
☐ May receive more care and attention from medical doctors and staff 
☐ May help my family understand an inherited disease/condition 
☐ None - I do not believe there are benefits 
☐ Other (please specify) ………………. 
12) Which TWO of the following reasons do you feel best describe why most people 
participate in clinical research studies? (select up to TWO) 
☐ To help others who may suffer from my disease/condition 
☐ To follow-through on a doctor's recommendation to participate in a research study 
☐ To receive monetary compensation (money) 
☐ To help scientists understand more about how to treat my disease/condition 
☐ To receive free medication (if applicable in your country) 
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☐ To receive free medical procedures and care (if applicable in your country) 
☐ To follow-through on a recommendation from my family or friends 
☐ To find a cure or better treatment for my illness 
☐ To help family members who may have this disease or condition in the future 
☐ To receive more care and attention from medical doctors and staff 
☐ Other (please specify) ………………. 
13) The following statements describe how some people feel about clinical research 
studies. Please indicate how strongly you agree or disagree with these statements. 
People who participate in clinical research studies... 
 Strongly 
disagree 
Somewha
t disagree 
Neutral 
Somewha
t Agree 
Strongly 
agree 
Have access to the 
best doctors 
     
Get the best 
possible treatment 
     
Are like 
experimental test 
subjects as 
opposed to a 
patient/person 
     
Are making a 
contribution to 
science 
     
Have a chance to 
receive free 
medicine and care 
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 Strongly 
disagree 
Somewha
t disagree 
Neutral 
Somewha
t Agree 
Strongly 
agree 
Are taking a 
gamble with their 
health 
     
Learn more about 
their condition and 
health 
     
Spend a lot of time 
at the doctor's 
office 
     
Are part of an 
experiment to test 
medications/treat
ments already 
available to the 
public 
     
Are part of an 
experiment to test 
medications/treat
ments not already 
available to the 
public 
     
Receive more time 
and attention from 
medical experts 
     
14) In general, how willing would you be to participate in a clinical research study? 
☐ Very willing 
☐ Somewhat willing 
☐ Not very willing 
☐ Not at all willing 
☐ I am not sure 
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15) Before deciding to participate in a clinical research study, how important is 
knowing each of the following types of information to you? 
 Not at all 
important 
Not very 
important 
Somewhat 
important 
Very 
important 
Potential risks and benefits     
Physical location of the research 
center (distance from home or 
work) 
    
Length of participation in the 
clinical research study (time 
commitment) 
    
Number of study visits and types 
of medical procedures required 
    
Purpose of the clinical research 
study 
    
If I would have access to the 
study drug after my participation 
ended 
    
If my confidentiality would be 
protected 
    
If I would receive a summary of 
the study results after my 
participation ended 
    
Potential costs and 
reimbursements 
    
Hearing about the experiences 
of previous research participants 
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16) Have you ever tried to join (i.e., tried to participate in) a clinical research study? 
☐ Yes 
☐ No 
17) Which of the following are reasons why you would not be willing to participate in 
clinical research studies? (select all that apply) 
☐ I do not want to risk getting an inactive drug (also known as sugar pill or placebo) 
☐ I don't want to be treated like an experimental test subject as opposed to a 
patient/person 
☐ I am concerned about protecting my privacy 
☐ I have concerns about the risks associated with clinical research studies 
☐ Too much time is required to participate 
☐ I am not interested in clinical research 
☐ I do not know enough about clinical research 
☐ It costs too much money to participate 
☐ My health insurance does not cover the costs 
☐ My family/caregiver did not want me to participate 
☐ Online information convinced me not to participate 
☐ I could not afford the time away from my job 
☐ I have heard too many negative stories in the media and by word-of-mouth 
☐ I do not think clinical research studies are ethical 
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☐ I do not want to take a chance with my health 
☐ It is too difficult for me to get to the research center 
☐ I do not have any reason to participate 
☐ There are no reasons in particular 
☐ Other (please specify) ………………. 
18) Please rate each of the factors below on their likelihood of influencing your 
decision to participate in a clinical research study. 
 
Not at 
all 
likely 
Not very 
likely 
Neutral 
Somewhat 
likely 
Very 
likely 
If I had a terminal illness 
(incurable or fatal)  
     
If I thought a study drug 
might cure me 
     
If I knew that I would 
receive an active drug and 
not an inactive substance 
or sugar pill (placebo)  
     
If I received money for 
participating 
     
If I knew the risks 
associated with the 
treatment 
     
If I knew that it would not 
cost me anything to 
participate 
     
If I knew there were no 
risks involved 
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Not at 
all 
likely 
Not very 
likely 
Neutral 
Somewhat 
likely 
Very 
likely 
If my doctor recommended 
it 
     
If the treatment were free 
of charge to me  
     
If I thought the 
drug/treatment would help 
me 
     
If it were convenient for 
me to participate (e.g., 
convenient appointment 
times, the research center 
was not too far away)  
     
If I had a condition other 
than a terminal illness 
     
If there were no other 
medical options available 
to me 
     
If there were minimal side 
effects associated with the 
treatment 
     
If I thought the 
drug/treatment would help 
someone else in the future 
     
If I already take a 
drug/treatment 
manufactured by the 
pharmaceutical company 
sponsoring the study 
     
If I knew someone else 
with my condition was 
participating in the study 
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Not at 
all 
likely 
Not very 
likely 
Neutral 
Somewhat 
likely 
Very 
likely 
If my family 
recommended it 
     
If it were recommended 
via an online social 
network or disease forum 
     
If the time commitment 
was reasonable 
     
If I knew a summary of the 
research study results 
would be shared with me  
     
19) Have you ever participated in (i.e., joined or enrolled) a clinical research study? 
☐ Yes 
☐ No  
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Appendix D: Email Invitation 
 
To: Clinical Research Administration Program Alumni  
Subject: Clinical Research Survey 
Date: Tue, Jan 10, 2017 at 8:14 AM 
 
Good morning, 
You have been identified as one of the alumni of the Clinical Research 
Administration Graduate Program at Eastern Michigan University. You are invited to 
participate in a study for a graduate research project. The purpose of this study is to assess 
your willingness to participate in clinical trials. 
I would appreciate your willingness to participate in the study, and I value your 
feedback. This study consists of an on-line survey, and it should take about 7-12 minutes 
of your time. Your feedback is highly appreciated.  
If you have any questions or concerns, you can contact the researcher, Rania 
Felemban, at rfelemba@emich.edu. You can also contact the advisor, Dr. Irwin Martin, at 
imartin2@emich.edu. 
To begin, please click the survey URL below: 
https://www.surveymonkey.com/r/Felemban  
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Thank you for taking the time to participate in the survey. We truly value the 
information you have provided. By participating in this survey, you contributed to 
enhancing subject enrollment in clinical trials and better understanding the barrier to 
recruiting human subjects into clinical research. 
Regards, 
Rania Felemban 
A graduate student  
Clinical Research Master’s Program 
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Appendix E: Email Reminder 
 
To: Clinical Research Administration Program Alumni  
Subject: Clinical Research Survey 
Date: Tue, Jan 17, 2017 at 10:40 AM 
 
Good morning, 
This is a friendly reminder to participate in a study for a graduate research 
project. If you are already participated, please disregard this E-mail. 
You have been identified as one of the alumni of the Clinical Research 
Administration Graduate Program at Eastern Michigan University. You are invited to 
participate in a study for a graduate research project. The purpose of this study is to assess 
your willingness to participate in clinical trials. 
I would appreciate your willingness to participate in the study, and I value your 
feedback. This study consists of an on-line survey, and it should take about 7-12 minutes 
of your time. Your feedback is highly appreciated.  
If you have any questions or concerns, you can contact the researcher, Rania 
Felemban, at rfelemba@emich.edu. You can also contact the advisor, Dr. Irwin Martin, at 
imartin2@emich.edu. 
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To begin, please click the survey URL below: 
https://www.surveymonkey.com/r/Felemban  
Thank you for taking the time to participate in the survey. We truly value the 
information you have provided. By participating in this survey, you contributed to 
enhancing subject enrollment in clinical trials and better understanding the barrier to 
recruiting human subjects into clinical research. 
 
Regards, 
Rania Felemban 
A graduate student  
Clinical Research Master’s Program 
 
 
